Published in Diabetes on October 05, 2012
Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A (2013) 1.07
Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol (2015) 0.91
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes (2013) 0.90
Protective and antioxidant effects of PPARα in the ischemic retina. Invest Ophthalmol Vis Sci (2014) 0.88
α-Melanocyte-stimulating hormone protects retinal vascular endothelial cells from oxidative stress and apoptosis in a rat model of diabetes. PLoS One (2014) 0.88
Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina. J Clin Exp Ophthalmol (2013) 0.86
Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina. Am J Pathol (2014) 0.83
Peroxisome proliferator-activated receptor-α-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1α. J Biol Chem (2014) 0.82
PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway. Invest Ophthalmol Vis Sci (2014) 0.82
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol (2015) 0.80
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Diabetes (2013) 0.79
Diabetic Retinopathy: Animal Models, Therapies, and Perspectives. J Diabetes Res (2016) 0.79
Genomics in the neonatal nursery: Focus on ROP. Semin Perinatol (2015) 0.78
Optimal treatment of diabetic retinopathy. Ther Adv Endocrinol Metab (2013) 0.78
Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia. Exp Ther Med (2015) 0.78
Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy. Exp Eye Res (2015) 0.78
Molecular Implications of the PPARs in the Diabetic Eye. PPAR Res (2013) 0.78
Expression and Function of the Endocannabinoid System in the Retina and the Visual Brain. Neural Plast (2015) 0.77
Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review. Curr Med Chem (2015) 0.77
Enhanced apoptosis of monocytes from complication-free juvenile-onset diabetes mellitus type 1 may be ameliorated by TNF-α inhibitors. Mediators Inflamm (2014) 0.76
Small Heterodimer Partner and Innate Immune Regulation. Endocrinol Metab (Seoul) (2016) 0.76
Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy. Int J Ophthalmol (2016) 0.75
Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment. PPAR Res (2015) 0.75
Gene set enrichment analysis of pathways and transcription factors associated with diabetic retinopathy using a microarray dataset. Int J Mol Med (2015) 0.75
Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci (2017) 0.75
Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy. Invest Ophthalmol Vis Sci (2017) 0.75
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci (1994) 10.46
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
Diabetic retinopathy: more than meets the eye. Surv Ophthalmol (2002) 2.95
VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci (2003) 2.09
Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes (2002) 2.05
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia (2010) 1.88
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol (2009) 1.61
PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34
Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol (2006) 1.28
The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs (2004) 1.26
Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract (2006) 1.26
Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One (2011) 1.22
Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology (2005) 1.20
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J (2009) 1.17
Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res (1998) 1.15
Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci (2001) 1.11
Impacts of two point mutations of RPE65 from Leber's congenital amaurosis on the stability, subcellular localization and isomerohydrolase activity of RPE65. FEBS Lett (2006) 1.09
Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun (2000) 1.06
Advances in the medical treatment of diabetic retinopathy. Diabetes Care (2009) 1.06
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med (2003) 1.05
Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care (2004) 1.05
Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia (2003) 1.05
Oxygen-induced retinopathy in the rat model. Doc Ophthalmol (1990) 1.01
Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets (2010) 1.01
Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol (2012) 0.99
Dyslipoproteinemia and diabetes. Endocrinol Metab Clin North Am (1990) 0.98
Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am J Ophthalmol (2002) 0.95
Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci (2011) 0.93
Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol (1992) 0.92
Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia (2011) 0.89
Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders. Ger J Ophthalmol (1995) 0.87
Update on the treatment of diabetic retinopathy. ScientificWorldJournal (2008) 0.87
Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Burns (2012) 0.86
Fenofibrate for diabetic retinopathy. Lancet (2007) 0.86
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm (1979) 0.85
Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med (2009) 0.82
Application of Bradford's protein assay to chick brain subcellular fractions. J Biochem Biophys Methods (1980) 0.81
[Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years (author's transl)]. Arch Ophtalmol (Paris) (1977) 0.80
Vascular leakage stimulates phenotype alteration in ocular cells, contributing to the pathology of proliferative vitreoretinopathy. Med Hypotheses (1998) 0.80
Diabetes, microalbuminuria and hypertension. Clin Exp Hypertens (1999) 0.79
Modulatory effect of fenofibrate on endothelial production of neutrophil chemokines IL-8 and ENA-78. Cardiovasc Drugs Ther (2012) 0.79
Peroxisome proliferator activated receptor-α agonists suppress transforming growth factor-α-induced matrix metalloproteinase-9 expression in human keratinocytes. Clin Exp Dermatol (2011) 0.78
[Study of lipid metabolic coefficient K2 in patients with hyperlipoproteinemia type IV before and after reduction of triglyceride level by adapted diet therapy]. Nutr Metab (1979) 0.78
Diabetes-related eye disorders. J Natl Med Assoc (1993) 0.77
[Effect of procetofen on the lipoprotein profile in patients with type II hyperlipoproteinemia]. Med Welt (1979) 0.77
[Fenofibrate in the treatment of diabetic retinopathy]. Med Clin (Barc) (2008) 0.77
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science (2008) 6.86
Allocation concealment and blinding: when ignorance is bliss. Med J Aust (2005) 2.85
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes (2003) 2.79
Determining the sample size in a clinical trial. Med J Aust (2002) 2.51
Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J (2005) 2.47
Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J (2006) 2.12
Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care (2004) 2.11
Normobaric hypoxia training causes more weight loss than normoxia training after a 4-week residential camp for obese young adults. Sleep Breath (2013) 2.11
RDH10 is essential for synthesis of embryonic retinoic acid and is required for limb, craniofacial, and organ development. Genes Dev (2007) 2.10
Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust (2003) 2.06
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation (2005) 2.02
The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Res Clin Pract (2013) 1.97
Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci (2004) 1.89
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
PTEN/mTOR and axon regeneration. Exp Neurol (2010) 1.87
Retinyl esters are the substrate for isomerohydrolase. Biochemistry (2003) 1.85
Surgical treatment of Zenker's diverticulum. Dig Surg (2013) 1.84
Retinal vascular caliber and risk of retinopathy in young patients with type 1 diabetes. Ophthalmology (2006) 1.72
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol (2009) 1.69
Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol (2006) 1.67
Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol (2006) 1.67
Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol (2009) 1.61
Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation (2005) 1.55
High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care (2012) 1.55
Correlation of regenerable opsin with rod ERG signal in Rpe65-/- mice during development and aging. Invest Ophthalmol Vis Sci (2003) 1.52
Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. J Nutr (2010) 1.47
Statistical methods in clinical trials. Med J Aust (2003) 1.47
S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys (2006) 1.46
Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J Biol Chem (2007) 1.45
Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci (2008) 1.42
Putting results of a clinical trial into perspective. Med J Aust (2007) 1.42
Subgroup analysis in clinical trials. Med J Aust (2004) 1.42
Quantitative assessment of early diabetic retinopathy using fractal analysis. Diabetes Care (2008) 1.41
Randomisation in clinical trials. Med J Aust (2002) 1.40
Fetal lung epithelial ion channels relocate in the cell membrane during late gestation. Anat Rec (Hoboken) (2011) 1.39
Myxedema coma after esophagectomy. Ann Thorac Surg (2010) 1.39
Two point mutations of RPE65 from patients with retinal dystrophies decrease the stability of RPE65 protein and abolish its isomerohydrolase activity. J Biol Chem (2006) 1.38
Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res (2006) 1.38
Bone marrow lacks a transplantable progenitor for smooth muscle type alpha-actin-expressing cells. Stem Cells (2005) 1.38
Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes (2010) 1.36
The pathogenic role of the canonical Wnt pathway in age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.31
Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr (2010) 1.31
Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res (2009) 1.31
Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int (2003) 1.30
Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem (2002) 1.29
Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant (2005) 1.28
Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care (2008) 1.27
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26
IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol (2004) 1.25
Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes (2005) 1.25
Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care (2008) 1.25
Specifying objectives and outcomes for clinical trials. Med J Aust (2002) 1.24
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res (2009) 1.23
Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care (2003) 1.22
Berries: emerging impact on cardiovascular health. Nutr Rev (2010) 1.21
Why should a doctor be interested in oral disease? Expert Rev Cardiovasc Ther (2010) 1.18
Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care (2008) 1.18
Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci U S A (2010) 1.17
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J (2009) 1.17
Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein. J Mol Endocrinol (2008) 1.17
Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis (2006) 1.15
Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care (2005) 1.14
Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway. Diabetes (2010) 1.13
Freeze-dried strawberry powder improves lipid profile and lipid peroxidation in women with metabolic syndrome: baseline and post intervention effects. Nutr J (2009) 1.13
Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol (2008) 1.13
Identification of conserved histidines and glutamic acid as key residues for isomerohydrolase activity of RPE65, an enzyme of the visual cycle in the retinal pigment epithelium. FEBS Lett (2005) 1.12
Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care (2003) 1.12
Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Med Care (2009) 1.12
Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes (2006) 1.11
Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol (2011) 1.09
Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes (2009) 1.08
Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Med J Aust (2005) 1.08
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care (2011) 1.08
The 11-cis-retinol dehydrogenase activity of RDH10 and its interaction with visual cycle proteins. Invest Ophthalmol Vis Sci (2009) 1.07
Retinal preconditioning and the induction of heat-shock protein 27. Invest Ophthalmol Vis Sci (2003) 1.07
Comparison of arterial assessments in low and high vascular disease risk groups. Am J Hypertens (2004) 1.07
Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke (2005) 1.07
Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A (2013) 1.07
Role of the 9-methyl group of retinal in cone visual pigments. Biochemistry (2004) 1.07
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2010) 1.06
Birdsong performance and the evolution of simple (rather than elaborate) sexual signals. Am Nat (2011) 1.06
A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. Am J Med Sci (2005) 1.05
Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes (2012) 1.05